Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
In a Collection Review, Patrick Phillips and colleagues discuss developments in clinical trial design for the evaluation of TB therapeutics.
Saved in:
| Main Authors: | Patrick P J Phillips, Carole D Mitnick, James D Neaton, Payam Nahid, Christian Lienhardt, Andrew J Nunn |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2019-03-01
|
| Series: | PLoS Medicine |
| Online Access: | https://doi.org/10.1371/journal.pmed.1002767 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials.
by: Andrew Vernon, et al.
Published: (2019-12-01) -
Advances in clinical trial design: Weaving tomorrow's TB treatments.
by: Christian Lienhardt, et al.
Published: (2020-02-01) -
An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse.
by: Patrick P J Phillips, et al.
Published: (2013-01-01) -
Keeping up with a Quickly Diversifying Pharmaceutical Landscape
by: Alexandre Goyon
Published: (2024-09-01) -
A systematic review of reported cost for smear and culture tests during multidrug-resistant tuberculosis treatment.
by: Chunling Lu, et al.
Published: (2013-01-01)